Abstract:
Hepatitis C virus (HCV) is a causative agent that causes chronic liver diseases worldwide. It is a little, enclosed, single-stranded ribonucleic acid (RNA) virus. The recognition of the pathogenic HCV genotype is critical for the remedy of its sufferers. The aim of this study was to identify the HCV RNA genotype to decide the correct treatment of hepatitis C positive sufferers in Bangladesh. Blood samples were collected from 390 individuals and isolated RNA (60 µg) from blood plasma. Extracted RNA was used for quantitative HCV RNA, and complementary DNA (cDNA) was prepared by polymerase chain reaction (PCR) conducted by reverse transcriptase enzyme. This cDNA amplified in multiplex by RT-PCR, which was performed with specific set of primers. The HCV RNA genotype was detected 297 of 390 patients. Of the 390 test samples, 200 (51.28%) samples were from males and 190 (48.71%) were from females, with age ranging from 5 to 78 years. In all, 166 of 200 male samples and 131/190 female samples were found positive for HCV. Of these 390 participants included in the study, 213 (54.61%) were identified as genotype 3 positive, 78 (20%) as genotype 1 positive, 6 (1.53%) as genotype 6 positive, and the remaining 93 (23.85%) samples were unclassified due to low/undetected viral load. In this study, we detected the highest percentage (30.89%) of genotype 3 HCV in patients aged 51 to 60 years. The results suggested that genotype 3 HCV is frequently present in Bangladesh and it is usually responses better to interferon therapy. However, genotype 1 and 6 HCV have also been found circulating in this country, which demands longer treatments and effective control measures.
摘要:
丙型肝炎病毒(HCV)是导致全球慢性肝病的病原体。它是一个小,随函附上,单链核糖核酸(RNA)病毒。致病性HCV基因型的识别对于其患者的治疗至关重要。这项研究的目的是确定HCVRNA基因型,以决定孟加拉国丙型肝炎阳性患者的正确治疗方法。从390个个体收集血液样品,并从血浆中分离RNA(60μg)。提取的RNA用于定量HCVRNA,通过逆转录酶进行的聚合酶链反应(PCR)制备互补DNA(cDNA)。该cDNA通过RT-PCR多重扩增,这是用特定的引物组进行的。390例患者中检测到297个HCVRNA基因型。在390个测试样本中,200份(51.28%)样本来自男性,190份(48.71%)来自女性,年龄从5岁到78岁不等。总之,发现200个男性样本中的166个和131个/190个女性样本的HCV阳性。在纳入研究的390名参与者中,213(54.61%)被鉴定为基因型3阳性,78(20%)为基因型1阳性,6(1.53%)为基因型6阳性,其余93份(23.85%)样本因病毒载量低/未检出而未分类.在这项研究中,在51~60岁的患者中,我们检测到基因型3HCV的比例最高(30.89%).结果表明,基因型3HCV在孟加拉国经常出现,通常对干扰素治疗反应更好。然而,基因型1和6的HCV也被发现在这个国家流行,这需要更长时间的治疗和有效的控制措施。